Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00315393 |
Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) are two rare immune system disorders that cause the inflammation of blood vessels, or vasculitis. In order to properly treat these diseases, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of disease in people with WG or MPA.
Condition |
---|
Wegener's Granulomatosis Microscopic Polyangiitis |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Longitudinal Protocol for Wegener's Granulomatosis and Microscopic Polyangiitis |
Blood (serum and plasma), urine, and DNA
Estimated Enrollment: | 300 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | April 2016 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
WG and MPA are two autoimmune disorders that cause systemic vasculitis. WG commonly affects the upper respiratory tract, the lungs, and the kidneys. MPA is marked by kidney inflammation, weight loss, skin lesions, nerve damage, and fever. Many patients with WG or MPA show no visible symptoms of active disease; it is known that underlying subclinical disease activity leads to long-term damage in these patients. Also, because it is difficult to monitor WG and MPA disease activity, it is difficult for clinicians to know when and how to treat these patients. This study will use new scientific methods to identify new biomarkers that can be used to monitor disease activity in WG and MPA patients. These biomarkers may be used to help direct clinical care for WG and MPA patients and assist in future drug development.
This study will last 5 years. Study visits will occur monthly for the first year, then every 3 months thereafter for the remainder of the study. Blood and urine collection will occur at every visit. A physical exam and medical and medication history will occur every 3 months; also, participants will be asked to complete several questionnaires to assess disease activity, health status, and tobacco, alcohol, and drug use. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Individuals with Wegener's granulomatosis and microscopic polyangiitis. Enrollment will be sequential and participants will have disease in various stages and of different duration.
Inclusion Criteria:
For diagnosis of WG, meets at least 2 of the following 5 modified American College of Rheumatology (ACR) criteria:
For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
Exclusion Criteria:
United States, Maryland | |
The Johns Hopkins Vasculitis Center | Recruiting |
Baltimore, Maryland, United States, 21224 | |
Contact: Cynthia Bethea 410-550-4390 cbethea3@jhmi.edu | |
Principal Investigator: Philip Seo, MD, MHS | |
United States, Massachusetts | |
Boston University School of Medicine Arthritis Center | Recruiting |
Boston, Massachusetts, United States, 02118 | |
Contact: Jessica Martin 617-414-2507 jmartin@bu.edu | |
Principal Investigator: Peter A. Merkel, MD, MPH | |
Principal Investigator: Paul A. Monach, MD | |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Kathy Mieras 507-284-9187 mieras.kathleen@mayo.edu | |
Principal Investigator: Ulrich Specks, MD | |
Principal Investigator: Steven R. Ytterberg, MD | |
United States, Ohio | |
Cleveland Clinic Foundation | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Katherine Tuthill 216-444-5257 TUTHILLK@ccf.org | |
Principal Investigator: Carol A. Langford, MD, MHS | |
Canada, Ontario | |
Mount Sinai Hospital | Recruiting |
Toronto, Ontario, Canada, M5T 3L9 | |
Contact: Sara Sutherland 416-586-8616 SSutherland2@mtsinai.on.ca | |
Principal Investigator: Simon Carette, MD | |
St. Joseph's Healthcare | Recruiting |
Hamilton, Ontario, Canada | |
Contact: Sandra Messier 905-522-1155 ext 35873 smessier@stjoes.ca | |
Principal Investigator: Nader A. Khalidi, MD |
Study Chair: | Peter A. Merkel, MD, MPH | Boston University |
Principal Investigator: | Carol A. Langford, MD, MHS | The Cleveland Clinic |
Principal Investigator: | Philip Seo, MD, MHS | Johns Hopkins Vasculitis Center |
Principal Investigator: | Ulrich Specks, MD | Mayo Clinic |
Principal Investigator: | Steven R. Yetterberg, MD | Mayo Clinic |
Responsible Party: | Boston University School of Medicine ( Peter A. Merkey, MD, MPH ) |
Study ID Numbers: | RDCRN 5505, U54RR019497, VCRC 5505 |
Study First Received: | April 14, 2006 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00315393 |
Health Authority: | United States: Federal Government |
WG MPA |
Microscopic polyangiitis Lung Diseases, Interstitial Vasculitis Urologic Diseases Respiratory Tract Diseases |
Wegener Granulomatosis Lung Diseases Wegener's granulomatosis Vascular Diseases Kidney Diseases |
Cardiovascular Diseases |